Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Investing Activities (2020 - 2025)

Eton Pharmaceuticals' Cash from Investing Activities history spans 6 years, with the latest figure at -$284000.0 for Q3 2025.

  • For Q3 2025, Cash from Investing Activities changed N/A year-over-year to -$284000.0; the TTM value through Sep 2025 reached -$38.4 million, down 1345.84%, while the annual FY2024 figure was -$40.0 million, 5063.1% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$284000.0 at Eton Pharmaceuticals, up from -$38.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$2000.0 in Q3 2021 and bottomed at -$38.1 million in Q4 2024.
  • The 5-year median for Cash from Investing Activities is -$768000.0 (2022), against an average of -$4.7 million.
  • The largest YoY upside for Cash from Investing Activities was 99.63% in 2022 against a maximum downside of 99900.0% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$3.3 million in 2021, then soared by 99.63% to -$12000.0 in 2022, then plummeted by 6358.33% to -$775000.0 in 2023, then crashed by 4820.26% to -$38.1 million in 2024, then soared by 99.26% to -$284000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Cash from Investing Activities are -$284000.0 (Q3 2025), -$38.1 million (Q4 2024), and -$1.9 million (Q1 2024).